Close

OPKO Health (OPK) Announces EU Designation for Orphan Drug Status for Oligonucleotide to Treat Genetic Neurological Disorder

March 8, 2017 8:05 AM EST Send to a Friend
OPKO Health, Inc. (NASDAQ: OPK) through its subsidiaries, Eirgen Pharma Limited, Ireland and OPKO Pharmaceuticals LLC, has received notification from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login